This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Innovator Spotlight: Timothy Clyde Granade
Introduction: Timothy Clyde Granade is a dedicated inventor based in Conyers, Georgia, recognized for his contributions to the field of biomedical research. His work focuses on the development of innovative methods for detecting antiretroviral drugs, specifically emtricitabine. Granade's patent showcases a significant advancement in monitoring compliance with therapeutic protocols for patients.
Latest Patents: Granade holds a patent for a monoclonal antibody that specifically binds to emtricitabine (FTC, 2',3'-dideoxy-5-fluoro-3'-thiacytidine). This patent discloses methods utilizing these antibodies to detect FTC in samples, which can be pivotal in determining whether a subject is adhering to prescribed treatment regimens. Furthermore, the invention offers methods to assess the appropriate dosage of FTC for individual subjects, demonstrating a commitment to personalized medicine.
Career Highlights: Timothy Clyde Granade currently works for the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services. His role involves contributing to vital health initiatives and advancing medical research through innovative technologies. His unique expertise has helped shape new diagnostic tools aimed at improving patient outcomes.
Collaborations: Throughout his career, Granade has collaborated with esteemed colleagues such as Ae Saekhou Youngpairoj and William M Switzer. These partnerships reflect a collaborative spirit in the scientific community, emphasizing the importance of teamwork in the pursuit of groundbreaking medical advancements.
Conclusion: Timothy Clyde Granade exemplifies the innovative spirit necessary for progress in the healthcare sector. His patent for monoclonal antibodies targeting emtricitabine is a testament to his commitment to improving patient care and adherence to treatment protocols. As he continues his work with the Department of Health and Human Services, his contributions are likely to have lasting impacts on drug detection and patient compliance in antiretroviral therapy.